MY180109A - Computationally optimized broadly reactive antigens for human and avian h5n1 influenza - Google Patents

Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Info

Publication number
MY180109A
MY180109A MYPI2014002331A MYPI2014002331A MY180109A MY 180109 A MY180109 A MY 180109A MY PI2014002331 A MYPI2014002331 A MY PI2014002331A MY PI2014002331 A MYPI2014002331 A MY PI2014002331A MY 180109 A MY180109 A MY 180109A
Authority
MY
Malaysia
Prior art keywords
polypeptides
influenza
avian
human
optimized
Prior art date
Application number
MYPI2014002331A
Other languages
English (en)
Inventor
Ted M Ross
Corey J Crevar
Brendan M Giles
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of MY180109A publication Critical patent/MY180109A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2014002331A 2012-02-13 2013-02-08 Computationally optimized broadly reactive antigens for human and avian h5n1 influenza MY180109A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261597998P 2012-02-13 2012-02-13

Publications (1)

Publication Number Publication Date
MY180109A true MY180109A (en) 2020-11-23

Family

ID=48984611

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014002331A MY180109A (en) 2012-02-13 2013-02-08 Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Country Status (11)

Country Link
US (3) US9566327B2 (enExample)
EP (2) EP2814837B1 (enExample)
JP (1) JP6175452B2 (enExample)
CN (2) CN107188934A (enExample)
AU (2) AU2013221877B2 (enExample)
CA (1) CA2863949C (enExample)
IN (1) IN2014DN05695A (enExample)
MX (1) MX359071B (enExample)
MY (1) MY180109A (enExample)
SG (1) SG11201404147YA (enExample)
WO (1) WO2013122827A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
EP2616545B1 (en) * 2010-09-14 2018-08-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
CA2863949C (en) * 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
RU2639551C2 (ru) 2012-03-30 2017-12-21 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1
US9309290B2 (en) 2012-11-27 2016-04-12 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
JP6525214B2 (ja) * 2014-06-03 2019-06-05 国立研究開発法人農業・食品産業技術総合研究機構 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用
WO2016100926A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza
AU2016274770B2 (en) 2015-06-09 2020-11-12 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US11116832B2 (en) 2016-06-03 2021-09-14 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides
US12098166B2 (en) * 2018-11-06 2024-09-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition against avian influenza virus H5 subtype
WO2020172365A1 (en) * 2019-02-21 2020-08-27 University Of Georgia Research Foundation Broadly reactive immunogens of h5 influenza virus, compositions and methods of use thereof
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
CA3234653A1 (en) * 2021-10-06 2023-04-13 Diosynvax Ltd Influenza vaccines

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US20020106798A1 (en) 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CA2598884A1 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
CN1298845C (zh) 2005-09-02 2007-02-07 中国农业科学院哈尔滨兽医研究所 表达禽流感病毒H5亚型HA蛋白的重组新城疫LaSota弱毒疫苗株
EP1969510A2 (en) 2005-12-19 2008-09-17 Novartis Vaccines and Diagnostics S.r.l. Methods of clustering gene and protein sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
WO2007130327A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
KR20090050056A (ko) 2006-08-14 2009-05-19 메사츄세츠 인스티튜트 어브 테크놀로지 헤마글루티닌 폴리펩티드 및 시약 그리고 방법
US8980281B2 (en) 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
EP2217064A4 (en) 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
WO2010036970A2 (en) 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
US8871220B2 (en) 2009-04-03 2014-10-28 Merial Limited Newcastle disease virus vectored avian vaccines
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
EP2616545B1 (en) 2010-09-14 2018-08-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
RU2018113521A (ru) 2012-02-07 2019-03-04 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b
CA2863949C (en) * 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Also Published As

Publication number Publication date
MX359071B (es) 2018-09-13
EP2814837B1 (en) 2017-11-29
US9566327B2 (en) 2017-02-14
HK1203523A1 (en) 2015-10-30
EP2814837A4 (en) 2015-07-22
AU2013221877B2 (en) 2017-11-09
US20160022805A1 (en) 2016-01-28
CA2863949C (en) 2021-06-29
JP6175452B2 (ja) 2017-08-02
US20170107262A1 (en) 2017-04-20
US20190092820A1 (en) 2019-03-28
CN107188934A (zh) 2017-09-22
EP2814837A1 (en) 2014-12-24
AU2018200962A8 (en) 2018-03-15
EP3305806A1 (en) 2018-04-11
IN2014DN05695A (enExample) 2015-05-15
US10179805B2 (en) 2019-01-15
MX2014008949A (es) 2014-10-24
CA2863949A1 (en) 2013-08-22
JP2015512871A (ja) 2015-04-30
US10865228B2 (en) 2020-12-15
CN104144941A (zh) 2014-11-12
EP3305806B1 (en) 2020-08-26
CN104144941B (zh) 2017-06-09
AU2013221877A1 (en) 2014-08-28
AU2018200962A1 (en) 2018-03-01
AU2018200962B2 (en) 2019-06-06
SG11201404147YA (en) 2014-10-30
WO2013122827A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
MX345150B (es) Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MY192714A (en) Antibody neutralizing human respiratory syncytial virus
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
MX2014004214A (es) Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
WO2013044203A3 (en) Novel influenza hemagglutinin protein-based vaccines
MX357191B (es) Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas.
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
WO2012082803A3 (en) Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof
MX2013013228A (es) Particulas similares a virus y proceso para prepararlas.
HK1250662A1 (zh) 用於治疗癌症的免疫原性融合蛋白
MX363149B (es) Vacunas de nucleoproteina de la influenza.
DK201370530A (en) Salmonid alphavirus vaccine
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
MX2019007924A (es) Vacunas contra la influenza.
WO2013049535A3 (en) Influenza vaccine
TN2010000332A1 (en) Recombinant influenza virus-like particles (vlps)produced in transgenic plants expressing hemagglutinin